Press Releases
-
Mar 8, 2021
RMAT Designation Granted by FDA During Bleeding Disorders Awareness MonthBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to valoctocogene...
-
Mar 3, 2021Topline data expected to be available in mid-2022
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has completed full enrollment in a global Phase 2 randomized, placebo-controlled study of vosoritide, an...
-
Feb 25, 2021- Full-year 2020 Total Revenues Increased 9% to $1.86 billion
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended December 31, Twelve Months Ended December 31, 2020 2019 % Change 2020 2019 % Change Total...
-
Feb 24, 2021- 2021 SVB Leerink Global Healthcare Conference on February 26 at 11:20am ET
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in four upcoming virtual conferences. An audio webcast of the presentations will be available live. You...
-
Feb 18, 2021
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of former Goldman Sachs partner and executive in the...